September 2026
the ahs just changed when neurologists can prescribe the modern migraine drugs
On September 7, 2026, the American Headache Society published updated migraine prevention guidelines in Headache, the society's official journal — the first major revision since 2012. The shift is practical: the [AHS guidance](https://americanheadachesociety.org/news/updated-guideline-on-migraine-prevention-medications-for-adults) now positions CGRP-targeting drugs alongside older preventive treatments from the start, rather than as fallback options for patients who have already failed something else. Prior authorization rules at many insurers required documented failure on older drugs — beta blockers, anticonvulsants, antidepressants — before a CGRP biologic would be covered. Guidelines do not rewrite insurance contracts, but they give prescribers something to cite and insurers something harder to ignore. What the guidelines do not change is the molecule. CGRP — calcitonin gene-related peptide — is an endogenous neuropeptide your trigeminal nerves have been producing since before you had language for the pain it can generate. Eight FDA-approved drugs now target it. Neurologists just said to get there sooner. The biology is the same as it was last week.
The actual neuropeptide
cgrp lives in your trigeminal ganglia and its job is to signal pain — migraine is when it overdoes it
CGRP stands for calcitonin gene-related peptide — named for its genomic relationship to calcitonin, the thyroid hormone involved in calcium metabolism. They share a gene but express in different tissues: calcitonin in thyroid C cells, CGRP primarily in sensory neurons, especially the trigeminal ganglia, the nerve cluster responsible for sensation across the face and scalp. The [IUPHAR pharmacology database](https://www.guidetopharmacology.org/GRAC/DatabaseSearchForward?searchString=CGRP) catalogs two receptor subtypes that mediate its downstream effects. In normal physiology, CGRP is one of the most potent vasodilators known and a key modulator of pain-signal transmission at sensory nerve endings. During a migraine attack, trigeminal nerve fibers release large quantities of CGRP into the meningeal vasculature — the tissue surrounding the brain. The peptide then acts on receptors in blood vessel walls and sensory nerve endings, driving vasodilation and the inflammatory cascade that characterizes migraine pain. This is not a malfunction. CGRP is performing its normal signaling role. In migraine, the activation appears dysregulated or chronically elevated, and the downstream result — vasodilation, sensitization, pain — follows from there. Blocking the peptide or its receptor interrupts the loop.
The drug story
eight fda drugs, one molecule — and most people know the brand names but not the peptide
The public story about CGRP is almost entirely a brand-name story. Aimovig, Ajovy, Emgality, Vyepti, Nurtec ODT, Qulipta, Zavzpret — these are the names patients encounter after cycling through triptans, preventives, and years of clinic notes that say try something different next. What most patients were never told during that journey is that all these drugs trace back to one endogenous neuropeptide and a therapeutic rationale established decades before any of them entered clinical trials. Some block CGRP itself — the peptide — preventing it from reaching its receptor. Others block the CGRP receptor directly. The gepants, including rimegepant and atogepant, are small-molecule receptor antagonists that work for both acute migraine attacks and as daily preventives. Different delivery formats — monthly injections, quarterly infusions, daily oral tablets, nasal sprays — but the same molecular target. The brand competition is real and the market for migraine drugs is enormous. The which-drug-is-better conversation is ongoing and legitimate. What that conversation tends to lose is the biological origin: one neuropeptide, present in every brain, doing a job that evolution assigned it long before pharmaceutical companies discovered it could be blocked.
What the data shows
the clinical evidence for the cgrp drug class is among the strongest in modern neurology
CGRP's role in migraine was first documented in the 1980s, when researchers measured elevated plasma CGRP during acute attacks and showed that successful sumatriptan treatment normalized levels — one of the earliest molecular validations of the triptan mechanism. The [PubMed literature for CGRP migraine](https://pubmed.ncbi.nlm.nih.gov/?term=CGRP+migraine) now spans thousands of publications across basic science, clinical pharmacology, and outcomes research. The clinical evidence for the drug class built on this biology is among the most consistent in modern neurology. Phase 3 trials for erenumab, fremanezumab, galcanezumab, and eptinezumab all demonstrated statistically significant reductions in monthly migraine days versus placebo, including in patient populations that had previously failed multiple other preventive therapies. The gepants added an oral option with evidence for both acute and preventive use. A review published September 9, 2026 in [Frontiers in Pharmacology](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1924544/full) found that combining gepants with monoclonal antibodies as a dual-prevention strategy produces a statistically significant decrease in monthly headache days across combined clinical data. The translational chain from neuropeptide biology to approved medicine is one of the more complete stories in modern pharmacology.
Human-supported — PeptideFactCheck stance
strong biology, strong drug evidence, and a guideline shift that changes access without changing the science
CGRP holds the Human-supported evidence tier, and holds it decisively. The underlying biology is established and has been reproduced across decades of neuroscience research. The drug class built on it has clinical trial evidence — multiple large randomized controlled trials, extensive post-marketing safety data, and years of real-world prescribing — that most peptides in this catalog will never approach. Human-supported means useful signal, but internet claims may go beyond the data. For CGRP, the issue runs in the other direction: the endogenous molecule gets obscured by brand-name coverage that treats the drug market competition as the story and leaves the neuropeptide biology entirely offscreen. The September 7, 2026 guideline update is about access, not biology. Neurologists already knew the drugs worked. What constrained prescribing was a reimbursement structure that treated CGRP drugs as last resort. The updated AHS guidance pushes back on that by positioning them alongside older options rather than after them. Whether payers follow on any particular timeline is a question guidelines cannot answer. The molecule does not change either way. Source trail before certainty.
Editorial boundary
What this page will not do
It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.